title: Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
abstract: We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.
authors.forename: Gamal
authors.initials: G
authors.lastname: Sidra
authors.forename: Cathy D
authors.initials: CD
authors.lastname: Williams
authors.forename: Nigel H
authors.initials: NH
authors.lastname: Russell
authors.forename: Sonya
authors.initials: S
authors.lastname: Zaman
authors.forename: Bethan
authors.initials: B
authors.lastname: Myers
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Byrne
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012008:Recurrence; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D003520:Cyclophosphamide